SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA's upcoming earnings report is a major catalyst, with community members debating whether the company can meet high expectations and sustain the AI-driven market rally. Concerns about AI valuations and potential overspending on AI infrastructure are fueling uncertainty. Some traders are anticipating a volatile reaction regardless of the earnings outcome, while others see a buying opportunity if the stock dips.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors discuss the potential impact of government regulations and demand for battery metals, particularly in light of geopolitical factors influencing the supply chain. Community members are focused on upcoming permits and the company's potential role in securing critical mineral independence for the US. Bullish sentiment appears to be driven by insider activity and positive indicators despite recent price volatility.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

EOSE is trending due to a strategic order from Frontier Power, seen as a strong validation after a short seller report questioned the company's safety and projections. Community members are actively debating the stock's valuation and future potential, particularly its role in energy storage for AI data centers, while also discussing the implications of warrant expirations and short interest.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending due to an increased share repurchase program, authorized up to $35 million, sparking community debate about its impact. While some view the buyback as a positive signal of confidence before commercialization milestones, others question the timing given previous share dilutions and the CEO's history. Discussions also include the potential for revenue growth from Tonmya and analyst projections.

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Limited - ADR

Kazia Therapeutics

KZIA is trending due to positive early results from a breast cancer trial, showing a significant reduction in tumor cells, sparking optimism among investors. The community is actively discussing the potential for a short squeeze, fueled by the stock's low float and high short interest. Some traders caution about potential dilution, while others see significant upside based on the drug's potential and existing partnerships.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet ($STRK) is trending as discussions surge around its potential to scale Bitcoin through BTCFi incentives and zk rollup technology. The community is focused on the increasing amount of staked $STRK and $BTC on the platform, alongside the improved efficiency and lower fees resulting from recent upgrades. Some analysts suggest Starknet's advancements position it to significantly benefit from Ethereum's upcoming Dencun upgrade, attracting attention as a layer-2 solution.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Olema Pharmaceuticals Inc

Olema Pharmaceuticals is trending due to positive results from Roche's breast cancer drug trial, boosting confidence in Olema's similar treatment and leading to analyst upgrades. The community is discussing the potential for a short squeeze and a possible buyout, while also weighing the impact of a potential public offering. Overall, optimism around the stock's prospects in the breast cancer treatment space fuels the current interest.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid community discussion around the impending release of Epstein files and speculation about potential connections to prominent figures.  The community is divided, with some alleging a targeted attack against certain individuals, while others demand full transparency. Broader discussions encompass political affiliations and potential impacts on the stock.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as investors discuss recent insider buying and the potential award of a major NASA contract for a lunar terrain vehicle (LTV). The community is weighing the significance of the insider purchase, speculating it signals confidence in securing the LTV contract, while others analyze chart patterns and potential near-term price movements amid market volatility.

Qfin Holdings, Inc. is a holding company, which engages in the provision of AI-empowered Credit-Tech platform. It provides comprehensive suite of technology services to assist financial institutions and consumers and SMEs in the loan lifecycle, ranging from borrower acquisition, preliminary credit assessment, fund matching and post-facilitation services. It is dedicated to making credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions. The company was founded on July 25, 2016 and is headquartered in Shanghai, China.

Qfin Holdings Inc. - ADR

Qifu Technology Inc - ADR

QFIN is trending amid mixed sentiment regarding earnings and future performance, particularly in light of regulatory considerations in China. The community is actively debating the company's growth potential, comparing it to peers, and analyzing technical indicators. Option alerts and discussions around put contracts indicate hedging strategies are also being considered alongside bullish forecasts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanda Pharmaceuticals Surges 21% After Positive Tradipitant Trial In GLP-1 Adjunct Setting

(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) jumped 21.02% to $5.32, up $0.92, after announcing positive topline results from its phase III study of tradipitant in preventing nausea and vomiting...

Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients

Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticipated in H1 2026.read more...

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1...

Acadian Asset Management LLC Sells 155,159 Shares of Vanda Pharmaceuticals Inc. $VNDA

Acadian Asset Management LLC lessened its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 8.2% during the second quarter, according to the company in its most recent...

Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Misses Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -22.58% and -6.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results PR Newswire WASHINGTON, Oct. 29, 2025 Fanapt Q3 2025 net product...

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025 Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025 PR Newswire...

Retail chatter picked up around Vanda Pharmaceuticals on Thursday after the company formally asked U.S. Food and Drug Administration (FDA) Commissioner Martin Makary to review a decision upholding the approval of two generic versions of its sleep drug Hetlioz, intensifying its fight with regulators just days after winning a separate court battle.In a filing, Vanda said it wants Makary to examine the ruling issued in July by Jacqueline Corrigan-Curay, the outgoing director of the FDA’s Center for Drug Evaluation and Research (CDER).&nbsp;Her decision, made shortly before her retirement, sided with the Office of Generic Drugs in clearing two competing versions of Hetlioz despite what Vanda argues were “significant flaws” in the underlying studies.The company said regulators accepted bioequivalence studies conducted only in Indian male subjects and overlooked data inconsistencies, including one generic that showed blood exposure levels more than twice those seen with Hetlioz.&nbsp;Vanda also criticized what it described as an entrenched FDA bias toward approving generics “regardless of whether they meet the requisite legal and evidentiary standards.”The latest push comes just days after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-cuts-ozempic-cost-to-499-dollars-per-month-for-self-paying-patients/chsOfKDRdXE">Vanda scored a legal win in Washington</a>, where a federal appeals court threw out the FDA’s rejection of Hetlioz as a jet lag treatment.&nbsp;The judges faulted the agency for giving the application only a cursory review and sent it back, saying the FDA must now either approve the drug for that use or give Vanda a proper hearing.&nbsp;The ruling revived a regulatory dispute dating back to 2018, when Vanda first sought approval for the indication.Hetlioz is already cleared in the U.S. to treat Non-24-Hour Sleep-Wake Disorder and sleep problems linked to Smith-Magenis Syndrome. It remains one of Vanda’s key products, generating $16.2 million in the second quarter of 2025, about 31% of the company’s revenue.Vanda said bureaucrats have indicated it may take up to two months for the FDA’s Office of the Commissioner to decide whether Makary himself will review the generics decision.&nbsp;“It is time that the rule of law return to the FDA under Dr. Makary’s leadership,” the company said in its statement.On Stocktwits, retail sentiment for Vanda was ‘bullish’ amid ‘high’ message volume.<a href="https://stocktwits.com/symbol/VNDA">Vanda’s stock</a> has declined nearly 6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Stocktwits, retail sentiment for Vanda (VNDA) was ‘bullish’ amid ‘high’ message volume. (Photo credit: Getty Images)

Retail Buzz Builds As Vanda Urges FDA Chief To Revisit Hetlioz Generics Decision — Alleges “Bias Toward Approvals”

The company argues that regulators relied on narrow study populations and overlooked major data inconsistencies, raising concerns about patient safety.

Equity

Vanda Pharmaceuticals Inc. (VNDA) shares surged 9% on Monday after the company said that a Federal Appeals Court overturned the U.S. Food and Drug Administration’s order denying approval to its drug Hetlioz in the treatment of jet lag disorder.Vanda had submitted its application to the FDA seeking approval for Hetlioz to treat jet lag disorder in October 2018. A federal district court ordered the FDA to resolve the application or commence a hearing with respect to the application after the agency delayed it. However, instead of holding a hearing, the agency issued an order refusing to approve the application, and Vanda subsequently filed a petition for review with the U.S. Court of Appeals for the D.C. Circuit.The appeals court set aside the FDA’s action and stated that the agency’s "treatment of Vanda's evidence is cursory," the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://vandapharmaceuticalsinc.gcs-web.com/node/16556/pdf">said</a> on Monday. The court has remanded the case back to the FDA, where Vanda expects the FDA will either approve the drug application or the company will receive a hearing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/VNDA">Vanda</a> jumped from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume stayed at ‘low’ levels.&nbsp;<figure class="image"><img style="aspect-ratio:578/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_18_at_11_58_28_AM_png_ad9d75a67b.webp" alt="VNDA's Sentiment Meter and Message Volume as of 11:55 a.m. ET on Aug. 18, 2025 | Source: Stocktwits" width="578" height="63"><figcaption>VNDA's Sentiment Meter and Message Volume as of 11:55 a.m. ET on Aug. 18, 2025 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user expects the stock to hit over $5.<stembedurl>https://stocktwits.com/HorizonBull/message/625611441</stembedurl>Another opined that the legal turnaround is a “strongly bullish development” for Vanda.<stembedurl>https://stocktwits.com/BigSqueezeComing/message/625585269</stembedurl>Hetlioz is a prescription medicine approved to treat people with Non-24-Hour Sleep-Wake Disorder and to treat nighttime sleep disturbances in Smith-Magenis Syndrome (SMS).In the second quarter of 2025, Hetlioz's net sales were $16.2 million, accounting for nearly 31% of Vanda’s overall total revenues. VNDA stock is down by about 11% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-space-starlink-changes-to-south-africa-black-ownership-rules/chsOhmVRdXO">SpaceX Calls For Changes To South Africa’s Black Ownership Rules For Telecom Companies: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark 

The court has remanded the case back to the FDA, where Vanda expects the agency will either approve the drug application or the company will receive a hearing.

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -35.29% and -4.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Current Price	$5.35
Prev Close	$4.40
Open	$4.77
Dividend Yield	0.00%
50-Day Moving Average	$4.88
Beta	0.70
Avg. Volume	676,195.52
PE Ratio	-3.07

52-Week High	$5.70
52-Week Low	$3.81
Market Capitalization	$260.03M
EPS (Annual)	-$0.325
Price to Book	0.56
Revenue Per Employee	$540,141.30
Enterprise Value/EBITDA	N/A

VNDA
Vanda Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VNDA News

VNDAVanda Pharmaceuticals Inc